Veran Medical continues to rapidly innovate with the launch of new lung navigation software for their SPiN Thoracic Navigation System™. The next generation SPiN Drive® navigation software will debut at the American Thoracic Society annual meeting in Washington, D.C. on May 21-23 (booth #657). Veran’s SPiN System™, new lung navigation software, and navigated instrumentation are designed to continue to drive consistently higher bronchoscopy diagnostic yields and the faster diagnosis of lung cancer. The earlier patients are diagnosed, the faster they can receive life saving therapy and improve chances of survival.

Veran’s new SPiN Drive® navigation software continues to improve their already best-in-class software for Navigated Bronchoscopy and Navigated TTNA (SPiN Perc™) to sample suspicious lung lesions. The SPiN System™ is now capable of displaying a Volume Rendered (VR) View, enabling physicians to visualize and avoid blood vessels during a Navigated Bronchoscopy. The next generation SPiN Drive® software will now enable physicians to utilize the SPiN System™ for additional therapy delivery solutions – with new features including percutaneous ablation modeling, and percutaneous fiducial marker visualization and reporting using SPiN Perc™. These new software capabilities continue to expand the clinical value and utilization scenarios for the SPiN System™.

“We are excited to debut our next generation SPiN Drive® software to all the lung specialists attending ATS,” said Veran Medical CEO, Jason Pesterfield. “This new lung navigation software assists these physicians in the early detection and treatment of lung cancer and in turn helps us continue our mission to significantly improve long-term survival rates for lung cancer patients.”

Veran’s next generation SPiN Thoracic Navigation System™ offers an industry leading precision thoracic guidance platform that allows lung experts to seamlessly transition between a navigated endobronchial approach and a navigated transthoracic approach utilizing SPiN Perc™, to help physicians rapidly and definitively diagnose lung cancer. Published clinical studies utilizing a multi-modality approach, including Veran’s SPiN System™ and SPiN Perc™, have demonstrated a 92% diagnostic yield.

Lung Cancer remains the number one cancer killer in the United States. 94 million current or former smokers remain at elevated risk. More than 8 million people in the U.S. currently meet the criteria for lung cancer screening. When suspicious lesions are discovered, patients need answers. But mounting clinical data suggests that a large percentage of the hundreds of thousands of bronchoscopies performed every year on suspected lung cancer patients are non-diagnostic—delaying potential life saving therapy.

Amniox was excited to meet with nurses during WOCNext today! Stop by booth #505 tomorrow from 11 a.m. - 3 p.m. to learn how we can share best practices around wound care management. @WOCNSociety #WOCN #WOCNext #WOCNext2019 #Healthcare #Medicine #Nursing

Wow full house at the Tenant Experience Hot Takes session featuring our own @PhilariousRex! @BOMAConference #BOMA2019

Thanks to @inspiredoracle for this image!

#mentalhealth #stigma #cpmh

Our new #eBook shows 10 advanced #callanalytics📱reports you can use to significantly increase the impact of your marketing on business results. Link to download: https://t.co/r1O7OPsiLH